{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:04:43Z","timestamp":1792919083788,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["made available to the instititution"],"award-info":[{"award-number":["made available to the instititution"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66767-9","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:03:57Z","timestamp":1764093837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-1835","authenticated-orcid":false,"given":"Janneke W.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-0438","authenticated-orcid":false,"given":"Kylie","family":"Keijzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap A.","family":"van Doesum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke A. M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-1516","authenticated-orcid":false,"given":"Adrienne H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-4518","authenticated-orcid":false,"given":"Joyce","family":"van Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-2791","authenticated-orcid":false,"given":"Marjolijn N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-4173","authenticated-orcid":false,"given":"Frank R.","family":"Pierik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne V.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1050","authenticated-orcid":false,"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ungewickell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-4024","authenticated-orcid":false,"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-7425","authenticated-orcid":false,"given":"Elisabeth G. E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2860-8767","authenticated-orcid":false,"given":"Anne G. H.","family":"Niezink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-6950","authenticated-orcid":false,"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"66767_CR1","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1182\/bloodadvances.2020003848","volume":"5","author":"SS Neelapu","year":"2021","unstructured":"Neelapu, S. S. et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 5, 4149\u20134155 (2021).","journal-title":"Blood Adv."},{"key":"66767_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66767_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med"},{"key":"66767_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"66767_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"66767_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug Discov. 22, 976\u2013995 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66767_CR7","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T-cell efficacy in large B-cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"66767_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134612","volume":"5","author":"PH Chen","year":"2020","unstructured":"Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020).","journal-title":"JCI Insight"},{"key":"66767_CR9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter, L. et al. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat. Med. 28, 2601\u20132610 (2022).","journal-title":"Nat. Med."},{"key":"66767_CR10","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/cancers15174334","volume":"15","author":"AM Spanjaart","year":"2023","unstructured":"Spanjaart, A. M. et al. The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands. Cancers 15, 4334 (2023).","journal-title":"Cancers"},{"key":"66767_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"66767_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11052-z","volume":"7","author":"M Cohen","year":"2017","unstructured":"Cohen, M. et al. Cytotoxic response against Epstein-Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"66767_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.csbj.2023.01.023","volume":"21","author":"K Keijzer","year":"2023","unstructured":"Keijzer, K. et al. Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation. Comput. Struct. Biotechnol. J. 21, 1102\u20131114 (2023).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"66767_CR14","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","volume":"30","author":"H Hubbeling","year":"2024","unstructured":"Hubbeling, H. et al. Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma. Clin. Cancer Res 30, 5083\u20135093 (2024).","journal-title":"Clin. Cancer Res"},{"key":"66767_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01022-w","volume":"14","author":"K Keijzer","year":"2024","unstructured":"Keijzer, K. et al. Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma. Blood Cancer J. 14, 41 (2024).","journal-title":"Blood Cancer J."},{"key":"66767_CR16","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. The role of CD8 PET imaging in guiding cancer immunotherapy. Front. Immunol. 15, 1428541 (2024).","DOI":"10.3389\/fimmu.2024.1428541"},{"key":"66767_CR17","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei, W. et al. ImmunoPET: concept, design, and applications. Chem. Rev. 120, 3787\u20133851 (2020).","journal-title":"Chem. Rev."},{"key":"66767_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen, X. et al. 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat. Commun. 15, 8791 (2024).","journal-title":"Nat. Commun."},{"key":"66767_CR19","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.7150\/thno.87489","volume":"13","author":"K Kurtz","year":"2023","unstructured":"Kurtz, K. et al. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics 13, 5469\u20135482 (2023).","journal-title":"Theranostics"},{"key":"66767_CR20","doi-asserted-by":"publisher","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","volume":"9","author":"KV Keu","year":"2017","unstructured":"Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci. Transl. Med. 9, eaag2196 (2017).","journal-title":"Sci. Transl. Med."},{"key":"66767_CR21","doi-asserted-by":"publisher","first-page":"eaaw5096","DOI":"10.1126\/sciadv.aaw5096","volume":"5","author":"I Minn","year":"2019","unstructured":"Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci. Adv. 5, eaaw5096 (2019).","journal-title":"Sci. Adv."},{"key":"66767_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/2326-6066.CIR-20-0901","volume":"9","author":"R Sakemura","year":"2021","unstructured":"Sakemura, R. et al. Development of a clinically relevant reporter for chimeric antigen receptor T-cell expansion, trafficking, and toxicity. Cancer Immunol. Res. 9, 1035\u20131046 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"66767_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood.2023022717","volume":"144","author":"J Kaminski","year":"2024","unstructured":"Kaminski, J. et al. B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood 144, 46\u201360 (2024).","journal-title":"Blood"},{"key":"66767_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","volume":"3","author":"SL Meier","year":"2022","unstructured":"Meier, S. L., Satpathy, A. T. & Wells, D. K. Bystander T cells in cancer immunology and therapy. Nat. Cancer 3, 143\u2013155 (2022).","journal-title":"Nat. Cancer"},{"key":"66767_CR25","first-page":"827","volume":"618","author":"G Ortiz-Mu\u00f1oz","year":"2023","unstructured":"Ortiz-Mu\u00f1oz, G. et al. In situ tumour arrays reveal early environmental control of cancer immunity. Nat. Med 618, 827\u2013833 (2023).","journal-title":"Nat. Med"},{"key":"66767_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","volume":"43","author":"X Li","year":"2025","unstructured":"Li, X. et al. Large B-cell lymphoma microenvironment archetype profiles. Cancer Cell 43, 1347\u20131364.e13 (2025).","journal-title":"Cancer Cell"},{"key":"66767_CR27","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","volume":"8","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 8, 3314\u20133326 (2024).","journal-title":"Blood Adv."},{"key":"66767_CR28","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","volume":"5","author":"E Bourbon","year":"2021","unstructured":"Bourbon, E. et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 5, 3227\u20133239 (2021).","journal-title":"Blood Adv."},{"key":"66767_CR29","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1182\/blood-2022-171120","volume":"140","author":"R Nair","year":"2022","unstructured":"Nair, R. et al. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood 140, 3800\u20133802 (2022).","journal-title":"Blood"},{"key":"66767_CR30","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"66767_CR31","doi-asserted-by":"publisher","first-page":"e009510","DOI":"10.1136\/jitc-2024-009510","volume":"12","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells. J. Immunother. Cancer 12, e009510 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"66767_CR32","doi-asserted-by":"publisher","first-page":"100739","DOI":"10.1016\/j.iotech.2024.100739","volume":"24","author":"C Carcopino","year":"2024","unstructured":"Carcopino, C., Erdogan, E., Henrich, M. & Kobold, S. Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. Immunooncol. Technol. 24, 100739 (2024).","journal-title":"Immunooncol. Technol."},{"key":"66767_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"66767_CR34","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","volume":"8","author":"N Kostopoulos","year":"2024","unstructured":"Kostopoulos, N. et al. Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration. Blood Adv. 8, 6308\u20136320 (2024).","journal-title":"Blood Adv."},{"key":"66767_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41420-024-02245-3","volume":"10","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. Systemic tumor regression with synergy therapy: radiotherapy and CAR-T. Cell Death Discov. 10, 479 (2024).","journal-title":"Cell Death Discov."},{"key":"66767_CR36","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133067 (2014).","journal-title":"J. Clin. Oncol."},{"key":"66767_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1208\/s12248-019-0392-0","volume":"22","author":"H Gill","year":"2020","unstructured":"Gill, H. et al. The production, quality control, and characterization of ZED8, a CD8-specific 89Zr-labeled immuno-PET clinical imaging agent. AAPS J. 22, 22 (2020).","journal-title":"AAPS J."},{"key":"66767_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.121.261972","volume":"63","author":"GA Prenosil","year":"2022","unstructured":"Prenosil, G. A. et al. Performance characteristics of the Biograph Vision Quadra PET\/CT system with a long axial field of view using the NEMA NU 2-2018 standard. J. Nucl. Med 63, 476\u2013484 (2022).","journal-title":"J. Nucl. Med"},{"key":"66767_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2967\/jnumed.118.215418","volume":"60","author":"J van Sluis","year":"2019","unstructured":"van Sluis, J. et al. Performance characteristics of the digital biograph vision PET\/CT system. J. Nucl. Med. 60, 1031\u20131036 (2019).","journal-title":"J. Nucl. Med."},{"key":"66767_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-015-0132-1","volume":"2","author":"I Rausch","year":"2015","unstructured":"Rausch, I. et al. Performance evaluation of the Biograph mCT Flow PET\/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys. 2, 26 (2015).","journal-title":"EJNMMI Phys."},{"key":"66767_CR41","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","volume":"35","author":"R Boellaard","year":"2008","unstructured":"Boellaard, R. et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur. J. Nucl. Med Mol. Imaging 35, 2320\u20132333 (2008).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"66767_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328\u2013354 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"66767_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-019-0257-8","volume":"6","author":"A Kaalep","year":"2019","unstructured":"Kaalep, A. et al. Quantitative implications of the updated EARL 2019 PET\u2013CT performance standards. EJNMMI Phys. 6, 28 (2019).","journal-title":"EJNMMI Phys."},{"key":"66767_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal, J. et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radio. Artif. Intell. 5, 5 (2023).","journal-title":"Radio. Artif. Intell."},{"key":"66767_CR45","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov, A. et al. 3D Slicer as an image computing platform for the quantitative imaging network. Magn. Reson Imaging 30, 1323\u20131341 (2012).","journal-title":"Magn. Reson Imaging"},{"key":"66767_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00895-7","volume":"13","author":"WG Breen","year":"2023","unstructured":"Breen, W. G. et al. Metabolic PET\/CT analysis of aggressive non-Hodgkin lymphoma prior to axicabtagene ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 13, 1\u20135 (2023).","journal-title":"Blood Cancer J."},{"key":"66767_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/metabo11020072","volume":"11","author":"F Eude","year":"2021","unstructured":"Eude, F. et al. Reproducibility of baseline tumour metabolic volume measurements in diffuse large B-cell lymphoma: is there a superior method?. Metabolites 11, 1\u201316 (2021).","journal-title":"Metabolites"},{"key":"66767_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington, S. F. & Meignan, M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J. Nucl. Med 60, 1096\u20131102 (2019).","journal-title":"J. Nucl. Med"},{"key":"66767_CR49","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.3390\/cancers12102820","volume":"12","author":"ML Schubert","year":"2020","unstructured":"Schubert, M. L. et al. Assessment of CAR T cell frequencies in axicabtagene ciloleucel and tisagenlecleucel patients using duplex quantitative PCR. Cancers 12, 2820 (2020).","journal-title":"Cancers"},{"key":"66767_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"66767_CR51","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"66767_CR52","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1002\/sim.4368","volume":"30","author":"DJ Lorenz","year":"2011","unstructured":"Lorenz, D. J., Datta, S. & Harkema, S. J. Marginal association measures for clustered data. Stat. Med 30, 3181\u20133191 (2011).","journal-title":"Stat. Med"},{"key":"66767_CR53","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s11307-018-1200-4","volume":"20","author":"YWS Jauw","year":"2018","unstructured":"Jauw, Y. W. S. et al. Noise-induced variability of immuno-PET with zirconium-89-labeled antibodies: an analysis based on count-reduced clinical images. Mol. Imaging Biol. 20, 1025\u20131034 (2018).","journal-title":"Mol. Imaging Biol."},{"key":"66767_CR54","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","volume":"53","author":"MA Lodge","year":"2012","unstructured":"Lodge, M. A., Chaudhry, M. A. & Wahl, R. L. Noise considerations for PET quantification using maximum and peak standardized uptake value. J. Nucl. Med 53, 1041\u20131047 (2012).","journal-title":"J. Nucl. Med"},{"key":"66767_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v099.i08","volume":"99","author":"B S\u00e4fken","year":"2021","unstructured":"S\u00e4fken, B., R\u00fcgamer, D., Kneib, T. & Greven, S. Conditional model selection in mixed-effects models with caic4. J. Stat. Softw. 99, 1\u201330 (2021).","journal-title":"J. Stat. Softw."}],"updated-by":[{"DOI":"10.1038\/s41467-026-69473-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66767-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:02:14Z","timestamp":1770796934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66767-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66767"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66767-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-026-69473-2","URL":"https:\/\/doi.org\/10.1038\/s41467-026-69473-2","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.N.L.H. reports institutional financial support for advisory boards\/consultancy from Merck and institutional financial support for clinical and preclinical studies from Amgen, Bayer, and Servier. L.V.v.D received funding unrelated to this project from NWO ZonMw via the VENI (NWO-09150162010173), individual career development grant, and Dutch Cancer Society Young Investigator Grant (KWF-13529). A.D. received research funding from Takeda. A.U. and S.P.W. are employees and stockholders of Genentech Inc., a member of the Roche group. S.G.E. received teaching fees from MSD. E.G.E.d.V. reports institutional financial support for advisory boards\/consultancy from NSABP, Daiichi Sankyo, and Crescendo Biologics and institutional financial support for clinical trials or contracted research grants from Amgen, Genentech, Roche, Bayer, Servier, Regeneron, and Crescendo Biologics. A.G.H.N. received research funding from Siemens and Genentech. T.v.M. received research grants from Genentech, Celgene\/BMS, and Siemens made available to the institution; personal fees from Kite\/Gilead, Janssen, and Eli Lilly (advisory boards or consultancy); and honoraria from Kite\/Gilead and Celgene\/BMS (speaker fees). A.H.B. reports research grants from Siemens, paid to the institution, outside submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11629"}}